• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

SILDENAFIL Drug Record

  • Summary
  • Interactions
  • Claims
  • SILDENAFIL chembl:CHEMBL192 Approved

    Alternate Names:

    VIAGRA
    VIZARSIN
    HIP-0908
    HIP0908
    SILDENAFIL
    UK-92480
    REVATIO
    NIPATRA
    5-[2-ETHOXY-5-(4-METHYLPIPERAZIN-1-YLSULFONYL)PHENYL]-1-METHYL-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-7(6H)-ONE
    5-[2-ETHOXY-5-(4-METHYL-PIPERAZINE-1-SULFONYL)-PHENYL]-1-METHYL-3-PROPYL-1,6-DIHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE
    1-{[3-(4,7-DIHYDRO-1-METHYL-7-OXO-3-PROPYL-1H-PYRAZOLO[4,3-D]PYRIMIDIN-5-YL)-4-ETHOXYPHENYL]SULFONYL}-4-METHYLPIPERAZINE
    rxcui:136411
    chembl:CHEMBL192
    pubchem.compound:5212
    drugbank:00203
    chemidplus:139755-83-2

    Drug Info:

    Year of Approval 1998
    Drug Class anti-impotence agents
    Drug Indications for treatment of erectile dysfucntion,antihypertensive agent
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications for treatment of erectile dysfunction
    (1 More Sources)

    Publications:

    Rybalkin et al., 2003, PDE5 is converted to an activated state upon cGMP binding to the GAF A domain., EMBO J.
    Zoraghi et al., 2007, Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors., Biochemistry
    Wang et al., 2008, Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil., Mol. Pharmacol.
    Corbin et al., 2002, Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction., Urology
    Wang et al., 1999, [Mode of action of sildenafil]., Zhongguo Yi Xue Ke Xue Yuan Xue Bao
    Kruuse et al., 2003, Migraine can be induced by sildenafil without changes in middle cerebral artery diameter., Brain
    Wang et al., 2006, Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development., J. Biol. Chem.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Carson, 2003, Long-term use of sildenafil., Expert Opin Pharmacother
    Eisenhardt A et al., 2003, ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction., Urology
    de Denus S et al., 2018, CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction., Pharmacogenomics J
    Sperling H et al., 2003, Sildenafil response is influenced by the G protein beta 3 subunit GNB3 C825T polymorphism: a pilot study., J Urol
    Muniz JJ et al., 2013, Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction., Pharmacogenomics J
    Lacchini R et al., 2013, VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction., Pharmacogenomics J
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
  • SILDENAFIL   PDE5A

    Interaction Score: 5.11

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Duromist
    Novel drug target Established target
    Trial Name sildenafil citrate,Revatio, Viagra

    PMIDs:
    12554648 17979301 17959709 12414329 12567500 12477710 16735511 11752352 12614192


    Sources:
    TdgClinicalTrial TEND

  • SILDENAFIL   GNB3

    Interaction Score: 1.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12576843


    Sources:
    PharmGKB

  • SILDENAFIL   NOS3

    Interaction Score: 0.8

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22064666


    Sources:
    PharmGKB

  • SILDENAFIL   VEGFA

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007311


    Sources:
    PharmGKB

  • SILDENAFIL   ACE

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12837457


    Sources:
    PharmGKB

  • SILDENAFIL   CYP3A5

    Interaction Score: 0.17

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • SILDENAFIL   CYP3A4

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28440343


    Sources:
    DTC PharmGKB

  • TEND: SILDENAFIL

    • Version: 01-August-2011

    Alternate Names:
    SILDENAFIL Primary Drug Name

    Drug Info:
    Drug Class anti-impotence agents
    Year of Approval 1998

    Publications:

  • TdgClinicalTrial: SILDENAFIL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications for treatment of erectile dysfunction
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: sildenafil

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    de Denus S et al., 2018, CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction., Pharmacogenomics J
    Eisenhardt A et al., 2003, ACE gene I/D and NOS3 G894T polymorphisms and response to sildenafil in men with erectile dysfunction., Urology

  • DTC: SILDENAFIL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL192 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL192

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21